Sign in

Private company

Bavarian Nordic

Logo: Unknown author Unknown author, Public domain, via Wikimedia Commons4

Danish pharmaceutical company

Bavarian Nordic A/S is a Danish biotechnology company focused on the development, manufacturing and commercialization of vaccines. The company is headquartered in Hellerup, Denmark, with manufacturing facilities in Kvistgård, Denmark and Thörishaus near Bern, Switzerland. The company has research and development facilities in Martinsried, Germany, as well as offices in USA, Canada, and France.2 It employed 1,653 people in 2024.1 Its revenue was DKK 1.9 billion in 2021.1 Wikipedia text CC BY-SA 4.0

Last updated Oct 21, 2026.

Overview

Jul 1, 1992Founded1
  • Industrybiotechnology1
  • HeadquartersHellerup1
  • Websitewww.bavarian-nordic.com
  • Legal formaktieselskab1
  • Listed onNasdaq Copenhagen A/S (BAVA), OTC Markets Group (BVNRY)1
  • LEI2138006JCDVYIN6INP513
  • StatusActive3
  • LEI statusIssued and current3
  • Registered addressPHILIP HEYMANS ALLE 3, 2900 Hellerup, Denmark3
  • Registered withDanish Business Authority, 162711873

See how the biggest companies compare on our leaderboards

Dessaus Boulevard
Photo: Leif Jørgensen, CC BY-SA 3.0, via Wikimedia Commons6

Bavarian Nordic A/S is a Danish biotechnology company focused on the development, manufacturing and commercialization of vaccines. The company is headquartered in Hellerup, Denmark, with manufacturing facilities in Kvistgård, Denmark and Thörishaus near Bern, Switzerland. The company has research and development facilities in Martinsried, Germany, as well as offices in USA, Canada, and France. The company uses viral vectors and virus-like particles in its research and development.2

Corporate structure

Bavarian Nordic sits at the top of its group. 2 entities, 2 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

  • Bavarian Nordic Hellerup, Denmark
    • Bavarian Nordic (United States) Subsidiary · United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries, stakes and holdings from Wikidata (CC0). Each entity in the chart links to its source.

Leadership

Who has led Bavarian Nordic, and when. Pick a name to see everywhere that person has worked.

Products and brands

  • smallpox vaccine

Listed on Wikidata.1

Technologies

MVA-BN

MVA-BN is a proprietary technology developed by Bavarian Nordic. It is derived from the Modified vaccinia Ankara virus. MVA-BN is characterized by the inability to replicate in human cells, contrary to other vaccinia-based vaccines, which may replicate in humans, thus potentially causing severe and life-threatening side effects. Developed as the non-replicating smallpox and mpox vaccine, MVA-BN is approved in Canada as Imvamune, in the European Union, as Imvanex, and the United States as

Jynneos. The vaccine was supplied for emergency use to the U.S. Strategic National Stockpile as well as other government stockpiles.

The vaccine is being deployed worldwide to combat the 2022 mpox outbreak, leading to concerns over vaccine nationalism and hoarding by countries with pre-existing contracts.

Ebola vaccine development and production

The company has worked for several years with the NIAID on the development of a filovirus vaccine for Ebola and Marburg hemorrhagic fever diseases. In October 2014, following a successful pre-clinical demonstration of the combination vaccine regimen of its multivalent MVA-BN Filovirus vaccine and Crucell/Janssen's AdVac technology based on adenoviral vectors, Bavarian Nordic joined efforts with Crucell Holland B.V., one of the Janssen Pharmaceuticals companies of Johnson & Johnson to develop and manufacture this vaccine regimen intended for emergency use to help contain the outbreak in West Africa. In January 2015, the company had produced the first 400,000 doses of the vaccine and the first clinical trial of the vaccine regimen was initiated in the UK, with additional trials planned in the US and Africa. It was approved for medical use in the European Union in July 2020.

Read the full text

Marketed products and pipeline

Bavarian Nordic's marketed products and pipeline, as of June 2025.

From Wikipedia’s article on Bavarian Nordic, shared under CC BY-SA 4.0.5

Subsidiaries and ownership

Owners

Subsidiaries

  • Bavarian Nordic (United States)

From Wikidata.1

Acquisitions

In October 2019, it was announced that Bavarian Nordic would acquire travel vaccines Rabipur(/Rabavert) for rabies and Encepur for tick-borne encephalitis (TBE) from GlaxoSmithKline (GSK). In February 2023, it was announced that Bavarian Nordic would acquire travel vaccines Vivotif for typhoid fever and Vaxchora for cholera, in addition to a late-stage candidate for chikungunya, from Emergent BioSolutions.

From Wikipedia’s article on Bavarian Nordic, shared under CC BY-SA 4.0.5

Employees over time

  • 20241,6531

Revenue over time

As stated on Wikidata, in the currency reported.

Revenue

  • 20211.9B DKK1

Timeline

  1. Jul 1, 1992Founded Founded1

Calendar

Drug trials and FDA: coming up

  1. Nov 30, 2026Phase 2 trial readout expected Phase 2 trial of Jynneos and MVA-BN (Quail) in Monkeypox (Mpox): primary completion expected Nov 30, 2026 (ClinicalTrials.gov NCT07199569).7
  2. Feb 2027Phase 2 trial readout expected Phase 2 trial of MVA-BN-WEV in Encephalitis: primary completion expected Feb 2027 (ClinicalTrials.gov NCT06899802).8

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). Trials from ClinicalTrials.gov, as the sponsor registered them (expected dates are the sponsor's own and often move); approvals and advisory committee meetings from the FDA. The FDA does not publish its decision (PDUFA) dates. The full markets calendar

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8